Orienting project on crystal deposits in gout, CPPD, and osteoarthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, longitudinal observational project at IRCCS Galeazzi - Sant'Ambrogio Hospital enrolling consecutive outpatients with gout or CPPD and disease-controls with osteoarthritis. Participants receive routine clinical, laboratory, and imaging assessments (including ultrasound and X-rays) at baseline and every six months, with urgent visits as needed, and data are extracted from medical records. The first phase measures the extent of crystal deposits in joints and blood vessels, and the second phase monitors how deposits progress, how they associate with standard therapies, and whether they link to cardiovascular complications. Follow-up data may be collected for up to 10 years to capture long-term patterns and outcomes.

Why it matters

Who can join: the full rules

The inclusion criteria for CPPD patients are:

* Patients diagnosed with CPPD disease according to the ACR/EULAR 2023 classification criteria.
* Patients with evidence of asymptomatic CPPD on US or X-rays (not meeting the classification criteria) according to validated imaging definitions.
* Aged older than 18 years.
* Able to provide informed consent, according to requirements of local IRB/ethics committee.

The inclusion criteria for gout patients are:

* Patients diagnosed with gout according to the ACR/EULAR 2015 classification criteria.
* Aged older than 18 years.
* Able to provide informed consent, according to requirements of local IRB/ethics committee.

The inclusion criteria for disease controls are:

* A diagnosis of OA according to ACR classification criteria
* No evidence of uric acid or calcium pyrophosphate deposits on US
* Uric acid \< 6 mg/dL
* Aged older than 18 years.
* Able to provide informed consent, according to requirements of local IRB/ethics committee

The exclusion criteria for gout/CPPD patients are:

* Known history of other inflammatory arthropathies
* Unable to provide informed consent, according to requirements of local IRB/ethics committee.

The exclusion criteria for disease controls are:

* Known history of other inflammatory arthropathies
* Unable to provide informed consent, according to requirements of local IRB/ethics committee.

Where it's running

• IRCCS Ospedale Galeazzi-Sant'Ambrogio
  Milan, Milano, Italy Recruiting

Study contacts

• Principal investigator: Georgios Filippou, MD — Università degli Studi di Milano / IRCCS Ospedale Galeazzi-Sant'Ambrogio
• Study coordinator: Georgios Filippou, MD
• Email: georgios.filippou@grupposandonato.it
• Phone: 0039 0283502707

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment

  This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.

  Recruiting at 41 sites Phase 2 Crystalys Therapeutics · Birmingham, Alabama and 40 other locations · NCT07535034

• Remote monitoring for gout in primary care

  This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.

  Recruiting Diakonhjemmet Hospital · Oslo · NCT07490522

• Purified Cortrophin® Gel for treating acute gout flares at two dose levels

  This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.

  Recruiting Phase 4 Massachusetts General Hospital · Boston, Massachusetts · NCT07346079

• IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout

  This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.

  Recruiting at 35 sites Phase 2 Protalix · Glendale, Arizona and 34 other locations · NCT07280156

• Dotinurad versus allopurinol for lowering uric acid in gout

  This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.

  Recruiting at 103 sites Phase 3 Crystalys Therapeutics · Birmingham, Alabama and 118 other locations · NCT07089875

• Metformin for safety and benefit in people with gout

  This trial will test whether metformin is safe and helps reduce gout symptoms in people diagnosed with gout.

  Recruiting Phase 2 Tanta University · Tanta · NCT06924658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.